NASDAQ · Biotechnology · USD

NextCure, Inc. (NXTC) Stock Analysis

NextCure, Inc. (NXTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NXTC

$5.42

−$0.03 (−0.46%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NXTC with… →

NXTC Key Statistics

As of Oct 21, 2026

Trading

Open: $5.51
Previous Close: $5.44
Day's Range: 5.25–6.04
52-Week Range: 1.55–15.74
Volume: 71.52K
Beta: 1.35

Valuation

Market Cap: $24.79M
P/E Ratio: unprofitable
EPS (ttm): −8.71

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$55.84M
Shares Outstanding: 4.58M
1-Year Return: −54.07%

Dividend and dates

Avg Volume: 200.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NXTC closed at $5.42, −54.07% over 1 year.

NextCure, Inc. (NXTC) has a market capitalization of $24.79M.

In fiscal 2025, NXTC reported revenue of $0.00.

NXTC Stock Return by Calendar Year

NextCure, Inc. (NXTC) return since May 2019: what $10,000 became

1 year: $10,000 $4,593; −54.07%
5 years: $10,000 $532; −94.68%
Since May 2019: $10,000 $227; −97.73%

If you had invested $10,000 in NextCure, Inc. (NXTC) at the close on May 9, 2019, the earliest close on record here, it would have been worth $227 at the close on October 21, 2026: −97.73% in total, −39.84% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+183.07%−80.65%−44.95%−76.50%−19.15%−32.37%+53.37%−61.84%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	−61.84%
2025	+53.37%
2024	−32.37%
2023	−19.15%
2022	−76.50%
2021	−44.95%
2020	−80.65%
2019 (partial year)	+183.07%

As of October 21, 2026.

NXTC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$55.84M	—
2024	$0.00	−$55.65M	—
2023	$0.00	−$62.72M	—
2022	$0.00	−$74.73M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$57.62M	−$55.84M	—
2024	$0.00	—	−$57.21M	−$55.65M	—
2023	$0.00	—	−$67.64M	−$62.72M	—
2022	$0.00	—	−$75.91M	−$74.73M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

The market values NextCure, Inc. (NXTC) at $24.79M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 40.

NXTC last closed at $5.42 on October 21, 2026. That is −$0.03 (−0.46%) against the previous close. Over the past 52 weeks the price has ranged from $1.55 to $15.74. The latest close sits 249.35% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $55.84M. Trailing earnings per share are −8.71.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −54.07%. Across 5 years the annualized return works out at −44.40%. The reported beta is 1.35. Daily returns over the trailing 7 years annualize to a volatility of 149.5%.

Growth & Income

The record shows no dividend for NXTC.

The strongest complete calendar year on file is 2025 at +53.37%; the weakest is 2020 at −80.65%. Of the 6 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −61.84% year to date.

Peer Comparison

NextCure, Inc. (NXTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
NextCure, Inc.	NXTC	$24.79M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. NextCure, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.

Visit website →